---
title: Maintenance Gemcitabine in the Chinese Advanced Lung Cancer
nct_id: NCT01336192
overall_status: UNKNOWN
phase: PHASE4
sponsor: Tongji University
study_type: INTERVENTIONAL
primary_condition: Non Small Cell Lung Cancer
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01336192.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01336192"
ct_last_update_post_date: 2011-04-15
last_seen_at: "2026-05-12T07:20:11.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Maintenance Gemcitabine in the Chinese Advanced Lung Cancer

**Official Title:** Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin

**NCT ID:** [NCT01336192](https://clinicaltrials.gov/study/NCT01336192)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 240
- **Lead Sponsor:** Tongji University
- **Collaborators:** Shanghai Pulmonary Hospital, Shanghai, China
- **Conditions:** Non Small Cell Lung Cancer
- **Start Date:** 2011-04
- **Completion Date:** 2013-04
- **CT.gov Last Update:** 2011-04-15

## Brief Summary

Lung cancer, the most common cancer worldwide, remains the leading cause of cancer death. Approximately two-thirds of all patients with newly diagnosed non-small-cell lung cancer (NSCLC) present with advanced stage that palliative chemotherapy is the only appropriate measure. The standard treatment for this patient population consists of third generation platinum-based doublet regimen for no more than 6 cycles followed by watch and wait until disease progression (PD) before the administration of second-line and third-line systemic anticancer therapeutic agents. Patients who go on to receive second-line therapy represent a selected subgroup with an improved overall prognosis.

Switch maintenance therapy with pemetrexed or erlotinib in patients with advanced NSCLC without PD after first-line chemotherapy has been confirmed to improve progression free survival (PFS) and overall survival (OS) significantly compared with placebo in two large randomized controlled studies. However, continuation gemcitabine maintenance therapy in this setting yields conflicting results in the west, i.e.showing a prolongation of PFS without OS improvement. Thus, we investigate the efficacy and safety of continuation of gemcitabine maintenance therapy for patients with metastatic NSCLC with ECOG performance status of 0-1 and without PD after four cycles of first-line chemotherapy with gemcitabine and cisplatin in China.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Histologic or cytologic confirmed diagnosis of Stage IV NSCLC according to 2009 the seventh edition of TNM staging of lung tumors.
* No disease progression after four cycles of first-line chemotherapy with gemcitabine plus cisplatin (running period) within one month before the enrollment.
* Brain metastases are permitted if treated with full course of whole brain radiotherapy without the presence of symptomatic central nervous system metastases.
* ECOG score 0-1

Exclusion Criteria:

* First-line chemotherapy other than combination treatment of gemcitabine plus cisplatin
* Other therapy including targeted therapy, immunotherapy and prior radiotherapy for the treatment of the primary tumor prior to enrollment.
* Active infection
* Inadequate liver and renal function.
* Serious concomitant systemic disorder incompatible with the study.
* Second primary malignancy (except in situ carcinoma of the cervix, adequately treated basal cell carcinoma of the skin, T1 vocal cord cancer in remission, or prior malignancy treated more than 5 years prior enrollment without recurrence)
* Presence of the pregnancy
```

## Arms

- **Best supportive care** (NO_INTERVENTION) — Best supportive care
- **Maintenance gemcitabine** (EXPERIMENTAL) — Maintenance therapy of gemcitabine alone

## Interventions

- **Gemcitabine** (DRUG) — Gemcitabine 1250mg/m\^2 Day 1 and 8, 28 days per cycle until PD
- **Best supportive care** (DRUG) — Best supportive care

## Primary Outcomes

- **Progression free survival** _(time frame: 12 months)_ — From the start of maintenance therapy or Best Suppotive Care(BSC) until the date of documented progressive disease or death from any cause

## Secondary Outcomes

- **Overall Survival** _(time frame: 18 months)_
- **Response Rate** _(time frame: approximately 4 weeks)_
- **Time to The Progression** _(time frame: 18 months)_
- **Health Related Quality of Life** _(time frame: Approximately 4 weeks)_
- **Number of Participants with treatment-related grade III/IV adverse events** _(time frame: 6 months)_

## Locations (1)

- Shanghai Pulmonary Hospital Medical Oncology Department, Shanghai, Shanghai Municipality, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.shanghai pulmonary hospital medical oncology department|shanghai|shanghai municipality|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01336192.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01336192*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*